[
  {
    "ts": null,
    "headline": "Target upgraded, Stryker downgraded: Wall Street's top analyst calls",
    "summary": "Target upgraded, Stryker downgraded: Wall Street's top analyst calls",
    "url": "https://finnhub.io/api/news?id=1a40d8fc1a49c1e2d412f4207d8ba3ca85e0a96c2867694c47f47310f1ea7d1a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769524673,
      "headline": "Target upgraded, Stryker downgraded: Wall Street's top analyst calls",
      "id": 138270930,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "SYK",
      "source": "Yahoo",
      "summary": "Target upgraded, Stryker downgraded: Wall Street's top analyst calls",
      "url": "https://finnhub.io/api/news?id=1a40d8fc1a49c1e2d412f4207d8ba3ca85e0a96c2867694c47f47310f1ea7d1a"
    }
  },
  {
    "ts": null,
    "headline": "What Stryker (SYK)'s TD Cowen Downgrade on Valuation Grounds Means For Shareholders",
    "summary": "Earlier this week, TD Cowen downgraded Stryker from “Buy” to “Hold,” arguing that the medical device company’s current valuation already reflects its expected earnings growth. This shift highlights how differing analyst views, with some remaining positive and others turning more cautious, can quickly reshape sentiment around Stryker’s prospects. We’ll now examine how TD Cowen’s valuation concerns influence Stryker’s investment narrative and what this means for investors’ expectations. The...",
    "url": "https://finnhub.io/api/news?id=023086213ea732e7916f4dbc498d1109a901af8fec0f08758fe0ef86a0714c51",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769512250,
      "headline": "What Stryker (SYK)'s TD Cowen Downgrade on Valuation Grounds Means For Shareholders",
      "id": 138269302,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "SYK",
      "source": "Yahoo",
      "summary": "Earlier this week, TD Cowen downgraded Stryker from “Buy” to “Hold,” arguing that the medical device company’s current valuation already reflects its expected earnings growth. This shift highlights how differing analyst views, with some remaining positive and others turning more cautious, can quickly reshape sentiment around Stryker’s prospects. We’ll now examine how TD Cowen’s valuation concerns influence Stryker’s investment narrative and what this means for investors’ expectations. The...",
      "url": "https://finnhub.io/api/news?id=023086213ea732e7916f4dbc498d1109a901af8fec0f08758fe0ef86a0714c51"
    }
  }
]